Heregulin, Cysteine Rich-61 and Matrix Metalloproteinase 9 Expression in Human Carotid Atherosclerotic Plaques: Relationship with Clinical Data  by Sigala, F. et al.
Eur J Vasc Endovasc Surg 32, 238e245 (2006)
doi:10.1016/j.ejvs.2006.01.026, available online at http://www.sciencedirect.com onHeregulin, Cysteine Rich-61 and Matrix Metalloproteinase 9
Expression in Human Carotid Atherosclerotic Plaques:
Relationship with Clinical Data
F. Sigala,1,y S. Georgopoulos,1*,y E. Papalambros,1 D. Chasiotis,1
G. Vourliotakis,1 A. Niforou,2 A. Kotsinas,2 N. Kavantzas,3 E. Patsouris,3
V.G. Gorgoulis2 and E. Bastounis1
1Division of Vascular Surgery, 1st Department of Surgery, 2Department of Histology-Embryology,
and 3Department of Pathology, Medical School, University of Athens, Athens, Greece
Objectives. Heregulins (HRGs) are known to induce expression of angiogenic factors such as cysteine rich-61 (CYR61)
and collectively to promote neoangiogenesis. Along with extracellular matrix remodelling, mediated by matrix metallopro-
teinases (MMPs), these factors are important in atherogenesis. The aim of the present study was to investigate HRG,
CYR61 and MMP-9 expression and their relationship with clinical and histopathological findings in carotid occlusive
disease.
Materials and methods. Specimens of human carotid atherosclerotic plaque (n¼ 90) were obtained by endarterectomy.
Expression of HRG, CYR61 and MMP-9 was assessed by immunohistochemical and Western blot analysis. Associations
between protein expression and degree of carotid stenosis, presence of symptoms, presence of an infarct in CT scan and
carotid plaque histopathology were investigated.
Results. An increase in HRG, CYR61 and MMP-9 expression was found, particularly in neovascularized regions of the
plaques. High HRG expression was associated with the degree of carotid stenosis (p¼ 0.028) and plaque histopathology
(p¼ 0.002). More than half of specimens from plaques with >90% stenosis had intense expression of CYR61 (p¼ 0.047).
Increased expression of MMP-9 was associated with degree of stenosis and presence of cerebral infarct on CT scan
(p¼ 0.05).
Conclusion. HRG, CYR61 and MMP-9 are highly expressed in human atherosclerotic carotid plaques. The association
with the degree of stenosis and/or plaque histopathology implies an involvement in lesion progression.
Keywords: Heregulins; Cysteine rich-61; Matrix metalloproteinase 9; Carotid artery disease.Introduction
The complicated carotid plaque has received consider-
able attention because of its correlationwith the clinical
manifestations of carotid occlusive disease.1 Two histo-
logical features are critical in promoting plaque desta-
bilization: local inflammation and neovascularization.
The infiltration of atheromatous cap induces the ex-
pression of a number of growth factors and enzymes,
responsible for the resorption of extracellular matrix.2
Heregulins (HRGs) are a group of polypeptide
growth factors,3,4 that induce neoangiogenesis, when
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pression of angiogenetic factors such as vascular-
endothelial-growth-factor (VEGF) and cysteine-rich
61 (CYR61).5e7
CYR61 is a heparin-binding secreted system-rich
protein that is associated with the cell membrane
and the extracellular matrix. It binds directly to integ-
rins a6b1, avb3 and aiibb2 on various cell types.
8,9
CYR61 induces angiogenesis, adhesion and migration
of human peripheral blood monocytes, having crucial
role in the pathophysiological functions of monocytes
and macrophages in inflammation process.10 CYR61 is
over-expressed in atherosclerotic lesions in human
and mouse models.11
Matrix-metalloproteinases (MMPs) degrade extra-
cellular matrix, and thus weaken the fibrous cap of
the atheromatic lesions, promoting its rupture. They
also facilitate vascular smooth-muscle-cell (SMC)rved.
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que instability and the expression of HRG.12e16
Recently, we have shown that HGR and CYR61 are
over-expressed in human coronary atherosclerotic
lesions.17 Increasing HGR expression was associated
with the stages of the progressing lesions. In another
report, MMP-9 together with VEGF was over-
expressed in human carotid atherosclerotic plaques:18
expression was related to plaque instability, high de-
gree of stenosis and presence of symptomatic occlu-
sive disease.
Here, we have expanded our analysis of HRG,
CYR61 expression in human carotid plaques and ex-
amined cumulative expression with MMP-9 and as-
sessed the relationship of this protein expression
with the degree of carotid stenosis, presence of symp-




Carotid plaques (n¼ 90) were collected from 85 con-
secutive patients (70 men and 15 women, mean age
69 years) who had internal carotid artery stenosis
>70% and underwent carotid endarterectomy. All
cases were performed with shunt insertion and ve-
nous patch. Risk factors (smoking, hypertension, dia-
betes and hyperlipidemia) and vascular comorbidities
(ischemic heart disease, aneurysms, peripheral arte-
rial occlusive disease) were recorded (Table 1). This
set of lesions includes a previously examined cohort
of 53 carotid plaques for expression of MMP-9 and
VEGF.18 The study had the approval of the institu-
tion’s Ethical Review Board.
All patients were evaluated preoperatively by
a neurologist and were assigned as symptomatic
and asymptomatic. They also underwent a cerebral
CT scan for identification of possible brain infarcts.
Table 1. Patients’ demographics and risk factors







Ischemic heart disease 52 (61.1%)
Aneurysm 11 (12.9%)
Peripheral arterial occlusive disease 30 (35.2%)
Figures in parentheses indicate range or percentages.Arteriography of the carotid bifurcation was per-
formed in all patients and the degree of stenosis was
determined according to the NASCETcriteria.19 Based
on these measurements, stenotic lesions were divided
into three subgroups (70e79, 80e89, 90e99%).
Tissue preparation
All carotid plaque specimens were removed in the op-
erating room and were divided into two portions
along the longitudinal axis, to obtain similar portions,
with respect to protein content. One portion was col-
lected and fixed immediately in 10% neutral-buffered
solution containing about 4% formaldehyde for 24 h,
and embedded in paraffin for conventional histology
and immunohistochemistry. The second portion was
immediately stored at 70 C for future Western-
blotting analysis.
Histology
Routine haematoxylin and eosin staining was per-
formed for histological evaluation of the specimens.
Two pathologists, blinded to the clinical data, exam-
ined each specimen to assess atheromatous plaque
morphology, using the American Heart Association
classification of atherosclerotic plaques.20 The find-
ings of the two raters were identical. According to
this classification, carotid plaques were assigned as fi-
broatherotic (type V) or non-complicated and compli-
cated (type VI). The latter type included plaques with
intra-plaque hemorrhage, ulcer or thrombus, which
were considered unstable.
Thirty-five healthy carotid arteries obtained in
autopsies, served as tissue samples for the ‘baseline-
expression’ of the examined factors on human arteries.
Immunohistochemistry
Antibodies
For immunohistochemical analysis the following anti-
bodies were used: CYR61 (clone C-20) goat polyclonal
antibody (Santa-Cruz Biotechnology, Bioanalytica,
Athens, Greece) in a 1:50 dilution, heregulin (clone
7D5) mouse monoclonal antibody (Neomarkers, Bioa-
nalytica, Athens, Greece), in a dilution of 1:50, MMP-9
(clone: n/a) sheep polyclonal antibody (Biogenesis,
AlterChem, Athens, Greece), in a 1:100 dilution. In
serial sections we also determined the cellular pheno-
type of atherosclerotic plaques. To identify macro-
phages/foam cells, smooth muscle cells and
endothelial cells the following mouse monoclonal
antibodies were used, respectively: CD68 mouseEur J Vasc Endovasc Surg Vol 32, September 2006
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Athens, Greece) in 1:50 dilution and alpha-smooth
muscle actin (clone: 1A4) monoclonal antibody
(Dako, Kalifronas, Athens, Greece) in 1:50 dilution,
CD34 mouse (clone: QBE nd/10) monoclonal antibody
(Biogenex, AlterChem, Athens, Greece) in 1:50 dilution.
Method
Immunohistochemistry was performed according to
an indirect streptavidinebiotineperoxidase method.
In brief, 5 mm paraffin sections were placed on poly-
L-lysine-coated slides, dewaxed, rehydrated and incu-
bated for 30 min with 0.3% hydrogen peroxide to
quench the endogenous peroxidase activity. Unmask-
ing of the related proteins was carried out. The sec-
tions were incubated with the primary antibody at
a 1:50 dilution at 4 C overnight. Biotin-conjugated
secondary antibody was added at a 1:200 dilution
for 1 h at room temperature. Next stage comprised
30 min incubation in StreptAB complex (1:100 stock bi-
otin solution, 1:100 stock streptavidinehyperoxidase
solution) (Dako, Kalifronas, Athens, Greece). For color
development we used 3,3#-diaminobenzidine tetrahy-
drochloride (DAB, Sigma-Hellas, Athens, Greece) and
hematoxylin as a counterstain.
Evaluation
The staining pattern was considered positive only if
cytoplasmic signal was identified. Two independent
observers carried out slide examination. Inter-
observer variability was minimal.
Images were taken using a Zeiss Axiolab micro-
scope (Carl Zeiss GmbH, Jena, Germany) with a me-
chanical stage, fitted to a Sony-iris CCD videocamera
(Sony Corp., Tokyo, Japan). The videocamera was con-
nected to a pentium III personal computer loaded
with the appropriate image analysis software. Slides
were examined at high power magnification (400).
A first elaboration of digital images was done by using
the image scan pro software (Science GmbH, Erkrath,
Germany). Further evaluation was made via the Color
Estimation v.2.0, a specific application developed in
the Department of Pathology of Athens University in
a Microsoft Visual Basic 5.0 (Microsoft Corp., Red-
mond, WA) environment, for the evaluation of immu-
nohistochemical color images. The stained cells were
selected manually, but the measurement of staining
intensity was taken from the mean value of density,
which was calculated automatically.
Heregulin, CYR61, and MMP-9 expression in ca-
rotid atherosclerotic lesions was measured on a semi
quantitative scale ranging from 0 to 2, in which 0 indi-
cated absence of any expression; 1 weak expression
(þ) and two strong expression (þþ or þþþ). PotentialEur J Vasc Endovasc Surg Vol 32, September 2006differences of the expression of each factor among the
groups formed by the degree of carotid stenosis (three
groups: 70e79, 80e89, 90e99%), symptoms (two
groups: presence or absence of symptoms), CT scan
findings (two groups: presence or absence of an in-
farct), and carotid plaque morphology (two groups:
type V and type VI atheromatic plaque) were
examined.
Protein extraction and Western blot analysis
Total protein extraction
Frozen tissues samples were homogenized in 50 mM
Hepes pH 7.5, 150 mM NaCl, 15 mM beta-mercapto-
ethanol, 0.5 mM phenyl-methyl-sulfonyl-fluoride
(PMSF), 0.1% Nonidet P-40 (NP40) (Sigma-Hellas,
Athens, Greece). The homogenate was centrifuged at
3000 rpm (1000g) at 4 C for 5 min. The supernatant
was collected and adjusted to contain 1 mg/ml aproti-
nin, 1 mg/ml leupeptin and 1 mg/ml pepstatin A
(Merck, Athens, Greece).
Antibodies and controls
The anti-heregulin (7D5) mouse monoclonal antibody
(class: IgG2a; epitope: carboxy terminus, mouse ori-
gin) (Neomarkers, Bioanalytica, Athens, Greece) and
anti-CYR61 (C-20) goat polyclonal (Santa Cruz
Biotechnology, Bioanalytica, Athens, Greece) were
used as primary antibodies. A goat anti-mouse
horseradish-peroxidase-labeled anti-IgG (Sigma-Hellas,
Athens, Greece) and a rabbit anti-goat horseradish-
peroxidase-labeled anti-IgG (Santa Cruz Biotechnology,
Bioanalytica, Athens, Greece) were employed as
secondary antibodies, respectively. Extracts from the
human breast cancer cell lines MDA231 and MCF7
were used as positive controls. The anti-actin C-2
mouse monoclonal antibody (Santa Cruz Biotechnol-
ogy, Bioanalytica, Athens, Greece) was used for assess-
ing equal loading of total protein per sample.
Gel electrophoresis and blotting
Protein (50 mg) from total extracts of each sample were
adjusted with SDS PAGE sample buffer (NEB, Bioline,
Athens, Greece) and loaded on 10% SDS polyacryl-
amide gels. Gel electrophoresis and transfer to nitro-
cellulose membranes (Protran BA85, Schleicher and
Schuell, AlterChem, Athens, Greece) were performed
according to standard protocols. Each sample was
validated twice.
Signal development and quantitation
Blots were blocked for 2 h in 2% gelatin in TBS,
pH¼ 8.0 at RT. Subsequently, membranes were
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at RT, followed by 1 h incubation with secondary per-
oxidase labeled antibody (1/3500 dilution) at RT. Sig-
nal development was performed with the enhanced
SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Bioanalytica, Athens, Greece). Autoradiogra-
phies were scanned on a flatbed scanner and inte-
grated band intensities were estimated with the
Image-Pro Plus software, version 3.0 for Windows
(Media Cybernetics, Silver Spring, USA). HRG and
CYR61 expression for each case was normalized
against the corresponding integrated optical density
(IOD) of beta-actin, respectively. Specifically, IOD
values of HRG and CYR61, respectively, for each
case, was divided by the corresponding IOD beta-
actin value, and multiplied with a correction factor.
This factor represents deviation of the beta-actin
IOD value from the average beta-actin IOD of all
cases belonging to a group (normal cases, cases
with complicated and cases with non-complicated
plaques). Comparison of the average beta-actin IOD
values among these groups was performed to ex-
clude significant variations that may compromise
the use of beta-actin as a common reference baseline
( p¼ 0.534, ANOVA).
Statistics
Differences in the expression of the studied factors
among the predefined groups were tested by chi
square test and their correlations were estimated by
Kendall’s tau non-parametric coefficient. In Western
blot analysis, differences in the expression of heregu-
lin or CYR61 among all examined subgroups (normal,
complicated and non-complicated plaques) were per-
formed by ANOVA. All calculations were performed
by the SPSS 10.0. Values of p< 0.05 were considered
statistical significant.
Results
Description of clinico-pathological data
From the cohort of 90 carotid lesions, 57 were symp-
tomatic and 33 asymptomatic. However, only 36 cases
(including 17 silent infarcts) were associated with an
infarct in ipsilateral hemisphere and the remaining
had negative findings on brain CT scan. Twenty-two
lesions had stenosis less than 80%, 34 had 80e89%
stenosis, and 34 had greater than 90% stenosis. All
atherosclerotic carotid lesions were available for histo-
logic assessment: 54 were fibroatheromas (AHA classV) and 36 were complicated atherosclerotic plaques
(hemorrhage, ulceration, necrotic core) (AHA class VI).
Increased expression of HRG in carotid plaques is
associated with histological subtype and carotid stenosis
Immunohistochemical (IHC) analysis revealed a very
weak expression of HRG protein in normal carotid ar-
teries. In atherosclerotic plaques HRG IHC immuno-
staining was observed mainly in smooth muscle
cells (SMCs) (Fig. 1), and macrophages/foam cells in
the intima and in areas of neovascularization.
In IHC analysis, the expression of HRG did not dif-
fer between symptomatic and asymptomatic patients
( p¼ 0.453), nor between those who had or did not
have a cerebral infarct ( p¼ 0.647). There was, how-
ever, a significantly higher expression of HRG in com-
plicated (type VI) atheromatic carotid plaques
( p¼ 0.002). Specifically, strong expression of HRG
was observed in 50% of patients with complicated
(type VI) plaques compared to 18% of patients with
plaque type V (Table 2). Significantly increased HRG
levels also were found in patients with higher degree
of carotid stenosis ( p¼ 0.028).
HRG expression in normal and pathological carotid
arteries also was observed by Western blot analysis.
HRG levels were significantly different among these
groups, with highest levels observed in complicated
carotid plaques ( p¼ 0.004, ANOVA) (Fig. 2(A)
and (B)).
High CYR61 expression in carotid plaques is
associated with degree of stenosis
In normal carotid specimens slight CYR61 staining
was detected in extacellular matrix of the media and
adventitia. In contrast, considerable protein expres-
sion of CYR61 was demonstrated in atherosclerotic
plaques, particularly in SMCs of hyperplastic media
and of neointima. In areas of neovascularization, an
intense expression was observed in macrophages/
foam cells (Fig. 1). In small blood vessels, expression
of CYR61 was observed in smooth muscle cells,
whereas the endothelial cells show only slight
staining.
Statistically significant differences were observed
in CYR61 expression according to the degree of ca-
rotid stenosis, since approximately 60% of patients
with greater than 90% of stenosis had strong expres-
sion of CYR61 (Table 2). Associations between
CYR61 expression and the presence or absence of an
infarct on CT scan and the type of the atheromaticEur J Vasc Endovasc Surg Vol 32, September 2006
242 F. Sigala et al.Fig. 1. Representative immunohistochemical staining of HRG and CYR61 in complicated plaques (type VI). Staining of HRG
and CYR61 was performed in serial sections to assess their topological expression.plaque failed marginally to achieve statistical signifi-
cance (Table 2).
Western blot analysis confirmed that CYR61 also
was expressed in normal and pathological carotid
arteries. CYR61 levels were significantly different
between the groups, with the highest levels being
observed in complicated and atheromatic carotid pla-
ques. Thesewere significantly increased in comparison
to normal carotidswhere expression of CYR61was low
( p¼ 0.006, ANOVA) (Fig. 2(A) and (C)).
Increased MMP-9 expression in carotid plaques
The IHC presence of MMP-9 was detected particu-
larly in areas with intense inflammatory infiltration
and extracellular matrix. There was also significant
MMP-9 expression in macrophages and foam cells
around small vessels. The expression of MMP-9 wasEur J Vasc Endovasc Surg Vol 32, September 2006more intense in patients with higher degrees of ca-
rotid stenosis and in those who had a cerebral infarct,
although these relationship were weak ( p¼ 0.05)
(Table 2).
HRG, CYR61 and MMP-9 expression is
correlated in carotid plaques
A positive statistical correlation between HRG, CYR61
and MMP-9 IHC expression was found by pairwise
analysis ( p< 0.01, Kendall’s tau). A strong association
was found between CYR61 and MMP-9 (correlation
coefficient 0.530), followed by CYR61 and HRG
(correlation coefficient 0.439) and thirdly between
HRG and MMP-9 (correlation coefficient 0.352).
Analysis of IHC expression of HRG and CYR61 in
serial sections showed a co-localization of the signal
corresponding to these proteins, thus confirming theTable 2. Percentage of patients with strong expression of HRG, CYR61 and MMP-9 in the studied subgroups
Symptoms Degree of stenosis Infarct in CT Plaque type
Yes No 70e79 80e89 >90 Yes No V VI
HRG 33.3 29.8 45.5 14.7 38.2 27.8 33.3 18.5 50.0
p Value 0.814 0.028 0.647 0.002
CYR61 38.6 51.5 40.9 29.4 58.8 55.6 35.2 35.2 55.6
p Value 0.274 0.047 0.082 0.082
MMP-9 42.1 36.4 31.8 29.4 55.9 52.8 31.5 37.0 44.4
p Value 0.659 0.05 0.05 0.516
Immunostaing of heregulin, CYR61, and MMP-9 expression in carotid atherosclerotic lesions was measured on a semi quantitative scale
ranging from 0 to 2, in which 0 indicated absence of any expression; one weak expression (þ) and two strong expression (þþ or þþþ).
243HRG, CYR-61 and MMP-9 Expression in Carotid PlaquesFig. 2. Results of HRG and CYR61 expressions levels as assessed by Western blot analysis in normal carotid arteries, com-
plicated and non-complicated atherosclerotic plaques. (A) Representative Western blot analysis results for HRG and CYR61
expression in complicated, non-complicated carotid plaques and normal carotids. Beta-actin was used to assess equal load-
ing and normalization of HRG and CYR61 expression, respectively, for each case. (B) and (C) Box blots representing the
expression levels of HRG and CYR61, respectively, in complicated, non-complicated carotid plaques and normal carotids.
HRG and CYR61 expression levels were estimated by arbitrary optical integrated density units after normalization against
corresponding beta-actin expression.statistical association between their expression status
(Fig. 1).
Discussion
To the best of our knowledge, this is the first study in-
vestigating the expression of HRG in human carotid
atheromatous plaques and its association with disease
symptoms. HRG was expressed mainly in macro-
phages/foam cells of the intima and specifically
around the areas of neovascularization. Given that
HRG induces VEGF expression,21 this finding is consis-
tent with our previous observations showing VEGF
expression around the areas of neovascularization
in a subset of the carotid plaques used in the present
study.18 A significantly higher expression of HRG in
complicated carotid plaques and in higher degrees of
carotid stenosis indicates a possible role of this growth
factor in carotid plaque progression.
Heregulins (HRGs) are a group of pleiotropic
growth factors that are encoded by four different
HRG genes, investigated mostly in breast cancer pro-
gression.22 Although recent studies demonstrated that
HRG induces VEGF expression,21 its role in the pro-
gression of atherosclerosis remains unknown. We
have recently reported an intense expression of HRG
from monocytes/macrophages during atherogenesis,
which may facilitate their migration into the intima,induce cell proliferation and promote the establish-
ment and progression of the atherosclerotic lesion in
coronary arteries.17
In the present study, the majority of atherosclerotic
plaques with greater than 90% stenosis, showed an
intense expression of CYR61. In previous reports,
CYR61 expression has been associated with vascular
restenosis, angiogenesis and tumor growth.11,23 Hil-
fiker et al. reported a high expression of CYR61 at
both transcript and protein levels in atherosclerotic
tissue.11 They also demonstrated expression of CYR61
in the vascular wall in atherosclerotic aortae of
apoE-deficient mice.11 Our immunohistochemical
analysis revealed CYR61 staining in areas of neovas-
cularization, specifically in macrophages and SMCs.
It has been shown that CYR61 promotes endothelial
cell survival and formation of endothelial tubules
and acts directly upon endothelial cells to promote an-
giogenesis.24 CYR61 stimulates chemotaxis in endo-
thelial cells through the integrin anb3-dependent
pathway and induces neovascularization in vivo. It
seems that CYR61 may play a role in vascular remod-
eling during plaque formation and growth, which
may in later stages contribute to plaque instability
and the occurrence of symptoms.
In our study, there was a positive correlation be-
tween HRG and CYR61. In stained serial sections
there was a co-localization of HRG and CYR61 in
macrophage/monocytes, particularly in areas ofEur J Vasc Endovasc Surg Vol 32, September 2006
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HRG has paracrine effects in the mammary gland
stimulating the secretion of CYR6125 particularly in
highly invasive type.5 Recently, Panoutsopoulos et al.
showed that treatment of EA.hy926 cells (endothelial
cell line) with HRG resulted in upregulation of
CYR61 expression, indicating that HRG has a direct
effect on the regulation of CYR61 in endothelial cells.
HRG also induces VEGF expression and secretion in
EA.hy926 cells supporting its participating in athero-
sclerotic process. In coronary arteriosclerotic lesions
the above authors demonstrated that the expression
of HRG and CYR61 colocalises in the intima of
atherosclerotic lesions and that activated monocyte/
macrophage expressed both HRG and CYR61.17 It is
possible that HRG regulates CYR61 expression in
macrophages.
Several studies have implicated matrix metallopro-
teinases (MMPs) in the disruption of carotid athero-
sclerotic plaques13 and the onset of ischemic
insult.14,15 We also found a relationship between the
degree of the stenosis and the expression of MMP-9.
It is interesting that there was a positive correlation
between MMP-9 and the expression of HRG and
CYR61. HRG or/and CYR61 possibly upregulate the
expression of MMP-9.16,22 CYR61 also can regulate
the production and/or activity of other angiogenic
molecules, particularly VEGF, as well molecules that
affect the integrity or stability of the ECM such as
MMPs.26 Recently, we have showed a positive correla-
tion between MMP-9 and VEGF in a smaller study.18
Therefore, that CYR61 may have a paracrine action
participating in variable direct and indirect mecha-
nisms by which atherosclerotic process is regulated
at multiple control points.
In conclusion, the over-expression of HRG and
CYR61 appears to be associated with severe athero-
sclerosis of carotid arteries, while both molecules are
associated with the expression of MMP-9. HRG and
CYR61 may be important factors in the development
of plaque growth and disruption.
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